Trials / Unknown
UnknownNCT04665063
A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd. · Industry
- Sex
- All
- Age
- 14 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, non-randomized, single-arm, open clinical trial.
Detailed description
A single car consists of scFv, hinge region, transmembrane region, costimulatory domain and zeta subunit of CD3.Prior to CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for adverse reactions and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Auto CAR-T | Biological: Auto CAR-T |
| DRUG | Cyclophosphamide,Fludarabine | Drug: Cyclophosphamide,Fludarabine |
| PROCEDURE | Leukapheresis | Leukapheresis |
Timeline
- Start date
- 2020-10-22
- Primary completion
- 2023-10-21
- Completion
- 2025-10-21
- First posted
- 2020-12-11
- Last updated
- 2020-12-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04665063. Inclusion in this directory is not an endorsement.